Form 8-K · Current Report · Filed 2026-07-08
Moderna Appoints Michael McDonnell to Board of Directors
Moderna, Inc. announced on July 8, 2026, the appointment of Michael McDonnell to its Board of Directors, effective July 8, 2026. Mr. McDonnell, a seasoned financial executive with over 35 years of experience, most recently served as Chief Financial Officer of Biogen Inc. He will also serve on the Board's Audit Committee. The appointment is expected to bring valuable financial leadership and strategic perspective to Moderna as it advances its pipeline and executes on its long-term strategy.
- Filer
- Moderna Inc. MRNA · NASDAQ
- Filed
- Accession
- 0001682852-26-000134
- CIK
- 0001682852
- Signal
- High impactHealthcare
- Source
- Official filing on sec.gov ↗
Items reported
Reported Item
Market reaction
Close before filing
$79.77
Next session
-4.0%
Since filing
-31.3%
Latest close
$54.82
What happened, not what will happen — closing prices around the filing date.
Precedent
Previous filings from MRNA reporting the same item, with the next session's move:
Insider tape
Within 45 days of this filing, MRNA insiders reported 54 Form 4 transactions — net selling of $5.4M.
About Moderna Inc.
Moderna Inc. is a biotechnology company focused on developing transformative medicines based on messenger RNA (mRNA) technology. Its primary function is to research and produce a broad spectrum of vaccines and therapeutics by leveraging its proprietary mRNA technology platform. Moderna is notably recognized for its pivotal role in the healthcare and pharmaceutical sector, particularly due to its development of one of the first COVID-19 vaccines to receive emergency use authorization. The company’s pipeline extends beyond infectious diseases, targeting therapeutic areas such as oncology, cardiovascular diseases, and rare genetic disorders. Headquartered in Cambridge, Massachusetts, Moderna takes a leading position in the biotechnology industry through its innovative approach to drug development, emphasizing rapid advancement from concept to clinical application. The company plays a crucial role in addressing global health challenges through its cutting-edge mRNA-based solutions.
Never miss another MRNA filing
Profitelligence watches EDGAR around the clock and alerts you within seconds.